Fig. 7: Increased osteosarcoma drug resistance due to DCUN1D5 upregulation. | Communications Biology

Fig. 7: Increased osteosarcoma drug resistance due to DCUN1D5 upregulation.

From: Single-cell analysis links DCUN1D5 to immune remodeling and cisplatin resistance in recurrent osteosarcoma

Fig. 7

A Correlation between DCUN1D5 expression and the half-maximal inhibitory concentration (IC50) values of various drugs in osteosarcoma tissue samples from the TARGET database. Each point represents a different drug, with the x-axis indicating DCUN1D5 expression levels and the y-axis showing the corresponding IC50 values. A positive correlation suggests that higher DCUN1D5 expression is associated with increased drug resistance. B Correlation between DCUN1D5 expression and the IC50 values of drugs in osteosarcoma tissue samples from the GSE21257 database. Like panel A, this graph demonstrates the relationship between DCUN1D5 expression and drug resistance, further supporting the hypothesis that DCUN1D5 plays a role in multidrug resistance in osteosarcoma. C Molecular interaction analysis between DCUN1D5 and primary osteosarcoma treatments, including methotrexate, doxorubicin, cisplatin, and Cyclophosphamide. The binding affinity values represent the interaction strength, with stronger interactions indicating a higher potential for DCUN1D5 to influence drug efficacy. This analysis highlights the potential of DCUN1D5 as a therapeutic target for overcoming drug resistance in osteosarcoma.

Back to article page